Conference Coverage (ICAAC)

Promising Results from Early GBS Vaccine Trials

Published in Vaccine Weekly, October 20th, 1997

Vaccination of mothers-to-be may soon eliminate the major cause of neonatal bacterial infections.

Up to 30 percent of all women carry group B streptococci (GBS) in their genital tracts. Half of these women pass the infection to their children during birth. Serious invasive GBS infections occur in two of every 1,000 U.S. infants; most of these infections occur before three months of age. Ten percent of infected infants die, and half of those who develop GBS meningitis develop long-term neurologic sequelae that can include seizures and mental retardation.

"Phase I and early Phase II clinical trials have been conducted with GBS polysaccharide-tetanus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry